SHOULDER INNOVATIONS, INC.
SINYSEHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | $47.3M | $31.6M |
| Operating income | −$26.3M | −$14.7M |
| Net income | −$40.4M | −$15.6M |
| Total assets | $169.9M | $43.1M |
| Total liabilities | $29.2M | $23.3M |
| Equity | $140.8M | −$54.7M |
| EPS (diluted) | $-4.65 | $-242.04 |
| Shares out. | 20.6M | 83,882 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −55.6%
- Net margin
- −85.3%
- Return on equity
- −28.7%
- Return on assets
- −23.8%
- Return on capital (ROCE)
- −16.9%
- Liabilities / assets
- 17.2%
- Debt / equity
- 0.21×
- Book value / share
- $6.82
- Revenue growth (YoY)
- 49.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.68safe
- Accruals / assets
- −6.9%clean
- Beneish M-Score
- -2.42normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 342,733 | 3.6 | -21.1% |
| Apr 30, 2026 | 434,559 | 6.9 | -8.7% |
| Apr 15, 2026 | 475,948 | 5.5 | +21.6% |
| Mar 31, 2026 | 391,514 | 2.6 | +27.1% |
| Mar 13, 2026 | 307,956 | 3.3 | +11.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.